WWL113 – 25 mg

Brand:
Cayman
CAS:
947669-86-5
Storage:
-20
UN-No:
Non-Hazardous - /

Mouse carboxylesterase 3 (Ces3, also named Ces 1d) mediates triglyceride hydrolysis in white adipose tissue, liberating free fatty acids into circulation.{26465} Although important for basal lipolysis, Ces3 expression can be induced by xenobiotics.{26466,26464} Ces3 activity is significantly elevated during adipocyte differentiation.{26463} WWL113 is a selective inhibitor of Ces3 and the structurally related Ces 1f (IC50 = ~0.1 µM) without significantly affecting several related enzymes.{26463} It significantly reduces basal lipolysis in adipocytes.{26463} More interestingly, WWL113 corrects multiple features of metabolic syndrome in obese-diabetic db/db mice, including changes in weight gain, glucose tolerance, and levels of nonesterified free fatty acids, triglycerides, total cholesterol, and fasted glucose.{26463} It has similar effects in mice with diet-induced obesity.{26463} WWL113 also inhibits the human ortholog of mouse Ces3, hCES1 (IC50 = ~50 nM), which has a similar tissue expression pattern to Ces3.{26464,26463}  

 

SKU: - Category:

Description

A selective inhibitor of the mouse carboxylesterases Ces3 and Ces 1f (IC50 = ~0.1 µM); corrects multiple features of metabolic syndrome in obese-diabetic db/db mice and in mice with diet-induced obesity; also inhibits hCES1, the human ortholog of mouse Ces3 (IC50 = ~50 nM)


Formal name: 4′-[[[methyl[[3-(4-pyridinyl)phenyl]methyl]amino]carbonyl]oxy]-[1,1′-biphenyl]-4-carboxylic acid, ethyl ester

Synonyms: 

Molecular weight: 466.5

CAS: 947669-86-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Metabolic Syndrome||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity